Meet Amy
With her mother diagnosed with breast cancer four years earlier, Amy was determined to obtain a mammogram to ensure everything was okay. Following her self-requested mammogram, Amy’s doctor discovered a small tumor that was confined to the milk ducts, known as Ductal Carcinoma in Situ, or DCIS. Amy, an Oncology Nurse, was familiar with Oncotype DX Breast Recurrence Score® test for invasive breast cancer and she had seen how the test could help inform treatment decisions for patients facing invasive disease. Amy was now grappling with a difficult decision of her own. Her doctors could not decide whether or not she would benefit from radiation. Amy and her medical team determined it was best for her to utilize the Oncotype DX Breast DCIS Score® test to help everyone understand her particular case better. Upon receiving her test results, Amy was so relieved to find out that her likelihood of tumor recurrence was very low.
“It was life altering for me. Everyone should have the knowledge and ability to ask their doctor if Oncotype DX® testing is right for them. We have a right to decide what breast cancer treatment is right for us. Don’t be afraid to be your own advocate.”
Learn how the DCIS Score test can help individualize your treatment
Learn about the DCIS Score testing process
In their own words: Stories from patients with non-invasive DCIS breast cancer
See FAQs and videos about the DCIS Score test
$0
financial responsibility for DCIS Score test when Medicare fee-for-service (FFS) coverage criteria are met
Medicare Advantage, which is provided by commercial insurance companies, may have different financial responsibility compared to Medicare FFS.
Learn about costs, coverage, and how Exact Sciences can help